Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium-Reference-Cited by-同舟云学术

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

Published:2014-11-19 Issue:12 Volume:89 Page:1159-1160
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Landgren Ola¹,Gormley Nicole²,Turley Danielle²,Owen Roger G.³,Rawstron Andy³,Paiva Bruno⁴,Barnett David⁵,Arroz Maria⁶,Wallace Paul⁷,Durie Brian⁸,Yuan Constance¹,Dogan Ahmet⁹,Stetler-Stevenson Maryalice¹,Marti Gerald E.²

Affiliation:

1. National Cancer Institute (NCI); Bethesda Maryland

2. U.S. Food and Drug Administration (FDA); Silver Spring Maryland

3. HMDS Laboratory; St James's Institute of Oncology; Leeds United Kingdom

4. Clínica Universidad de Navarra; Centro de Investigación Médica Aplicada (CIMA); Pamplona Spain; on behalf of the Spanish Myeloma Group (PETHEMA/GEM)

5. UK NEQAS for Leucocyte Immunophenotyping; Royal Hallamshire Hospital; Shefield England

6. Centro Hospitalar de Lisboa Ocidental (CHLO), HSFX; Clinical Pathology Department; Lisbon Portugal

7. Roswell Park Cancer Institute; Department of Flow and Image Cytometry; Buffalo New York

8. Cedars-Sinai Comprehensive Cancer Center; Los Angeles California

9. Hematopathology Service; Memorial Sloan-Kettering Cancer Center; New York New York

Funder

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Reference8 articles.

1. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma;Paiva;Blood,2012

2. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study;Rawstron;J Clin Oncol,2013

3. Pursuing the curative blueprint for early myeloma;Roschewski;Blood,2013

4. . 2014 http://www.fda.gov/medicaldevices/newsevents/workshopsconferences/ucm402038.htm

5. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma;Jakubowiak;Blood,2012

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma;Blood;2024-07-25

2. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma;Discover Oncology;2024-03-19

3. Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment;Critical Reviews in Oncology/Hematology;2023-03

4. Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines;Advanced Drug Delivery Reviews;2022-06

5. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis;Cytometry Part B: Clinical Cytometry;2022-01-10